ART in Adults & Adolescents

Editors:
Jennifer Janels, MD
Joseph pick, PharmD, AAHPV
Elizabeth Sherman, PharmD, AAHPV
Layout Editor:
Clint Ribbie, BS

This treatment guideline resource is a collaboration of the North and South Florida Southeast AETC partner sites

This resource summarizes critical information regarding antiretroviral agents approved for use in adults and adolescents such as adult dosing (including renal dosing recommendations), available dosage forms, side effects, and important patient (pl) counseling points. Unless otherwise noted, information is adapted from the Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf Accessed December 15, 2016.

**Recommended Regimen Options (All rated BI or BI+)**

** INSTI-Based**
- Daltegravir/abacavir/tamivudine* (Truvada*) - Only if HLA-B*5701 negative

** PI-Based**
- Darunavir/cobicistat* (Prezista®) - Only if boosted PI resistance

** Alternative Regimen Options:**
- Effective regimens but have potential drug interactions. Should be considered for patients who are intolerant of regimens listed above. Have limited data for use in certain patient populations, or have less randomized clinical trial data. May be preferred in some pts. (All rated BI or BI+)

**NRTI-Based**
- Elvitegravir/tenofovir disoproxil fumarate/emtricitabine* (Atripla®)

- Elvitegravir/tenofovir alafenamide/emtricitabine* (Biktarvy®)

- Rilpivirine/tenofovir alafenamide/emtricitabine* (Complera®)

- Rilpivirine/tenofovir alafenamide/emtricitabine* (Odefsey®)

- If pre-ART viral load < 10,000 copies/mL and HLA-B*5701 negative

**Other Regimens when Tenofovir alafenamide, Rilpivirine disopruise or, Abacavir cannot be Used**
- Darunavir/or ganavir (Prezista®) + abacavir/tamivudine* (Epivir®) - Only if HLA-B*5701 negative

** Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)**

**Class adverse effects:** Lactic acidosis and hepatic steatosis

**Abacavir (Ziagen), ABC**
- [package insert]
- Dose forms: 300 mg tab, 20 mg/mL soln (240 mL bottle)
- Also available in combination products: Truvada®, Atripla®, Complera®

**Emtricitabine (Emtriva), FTC**
- [package insert]
- Dose forms: 200 mg cap, 10 mg/mL soln (170 mL bottle)
- Also available in combination products: Truvada®, Atripla®, Complera®, Descovy®, Odefsey®, Stemark®, Triumeq®

**Mefloquine (Lariam), MQ**
- [package insert]
- Dose forms: 250 mg cap, 250 mg tab, 500 mg tab

**Nevirapine (Viramune), NVP**
- [package insert]
- Dose forms: 75 mg tab, 100 mg tab, 150 mg tab

**Rilpivirine (Edurant), RPV**
- [package insert]
- Dose forms: 250 mg tab, 200 mg cap, 50 mg/mL soln (240 mL bottle)

**Ritonavir (Norvir), RTV**
- [package insert]
- Dose forms: 100 mg tab, 200 mg tab, 500 mg tab

**Stavudine (Zerit), D4T**
- [package insert]
- Dose forms: 4 mg/mL soln (300 mL bottle)

**Tenofovir Disoproxil Fumarate (Viread), TDF**
- [package insert]
- Dose forms: 240 mg tab, 180 mg tab, 360 mg tab

**Zidovudine (AZT, Retrovir), ZDV**
- [package insert]
- Dose forms: 100 mg tab, 60 mg/mL soln (300 mL bottle)